

MacroGenics Inc

CORTELLIS COMPANY DETAILED PIPELINE REPORT

A comprehensive coverage of the the company's drug pipeline portfolio including detailed product records.

Publication Date: 06-Aug-2014

THOMSON REUTERS

3 Times Square
New York, New York 10036
United States

Tel: +1 646 223 4000

thomsonreuters.com

[Return to Table of Contents](#)

ABOUT CORTELLIS COMPANY DETAILED PIPELINE REPORT

Thomson Reuters provides the knowledge, tools, and expertise to help support drug discovery and development activities, IP portfolio optimization, identification of licensing and partnering opportunities, delivery of successful regulatory submissions, and the ability to keep current with the rapidly-changing pharmaceutical and chemical markets, supporting informed, early decisions.

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information. From drug discovery and development activities to patent reports, the latest deals, and partnering opportunities, *Cortellis* can provide the confidence to make the most informed business decisions, faster. *Cortellis for Competitive Intelligence* provides accurate and validated information on pharmaceutical and biotechnology companies globally, their drug pipelines, deals, patents, and clinical trials, plus breaking industry news and conference coverage. All contained in one simple, highly intuitive research platform.

Cortellis Company Detailed Pipeline reports are the second in a series of that track pharmaceutical and biotechnology companies worldwide. All *Cortellis for Competitive Intelligence* content is subject to the most comprehensive editorial review process available, conducted by scientists, pharma professionals, regulatory experts, and generics specialists. Featuring timely drug pipeline information expertly uncovered and integrated from over 400 global meetings each year, you'll always be on top of the latest developments.

Chosen by leading life sciences companies, their executives and investors, *Cortellis for Competitive Intelligence* accelerates your deal-making and gives you timely insights on the development landscape.

Discover undiscovered opportunities in drug development and licensing faster with *Thomson Reuters Cortellis™ for Competitive Intelligence*

DISCLAIMER

The information contained in this report is based on sources believed to be correct but Thomson Reuters does not guarantee the accuracy, timeliness, or completeness of this information. Opinions, if any, are those held by the author of any individual report or article at the time of initial publication and do not necessarily reflect the views of Thomson Reuters.

Information in this report on companies is intended for reference use only, and does not constitute a recommendation to buy or sell any particular security or other investment and does not constitute an offer to buy from or sell to any particular investor. Any company or securities mentioned in this report may not be suitable for any particular investor, depending on that investor's financial position and needs.

[Return to Table of Contents](#)



GLOSSARY

Number of Drugs in Active Development

Number of drugs associated with the company or subsidiary that are currently in active development, i.e. the development status for the drug(s) is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

Number of Inactive Drugs

Number of drugs associated with the company or subsidiary that are currently classified as inactive, i.e. where the development status for the drug(s) is one of the following: No Development Reported, Discontinued, or Withdrawn.

Number of Patents as Owner

Number of patents associated with the company where the company is listed as owner; i.e. the relationship type (or way the patent refers to the company) is: Patent Assignee/Owner, Patent owner (not assignee), Licensee for development and marketing, Licensee – marketing only (Distributor), Patent assignee of family member, Inferred assignee.

Number of Patents as Third Party

Number of patents associated with the company where the company is listed as third party; i.e. the relationship type (or way the patent refers to the company) is: Patent assignee (not owner), Ex-Licensee for development and marketing, Ex-Licensee marketing only (Distributor), Customer of technology, Ex-Customer of technology, Patent opponent or infringer, Affiliate organization of inventor, Owner of underlying technology.

Patents summary table

This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

Number of Deals

A count of deals where the company or one of its subsidiaries is the primary company.

Key Indications

Displays top ten key indications for the company and its subsidiaries based on frequency (indications occurring with high and identical frequency are always included, and this may result in more than ten Key Indications being listed). Includes both indications associated with patents where the company is patent owner and indications associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

Key Target-based Actions

Displays top ten key target-based actions for the company and its subsidiaries based on frequency (actions occurring with high and identical frequency are always included, and this may result in more than ten Key Target-based Actions being listed). Includes both target-based actions associated with patents where the company patent owner and target-based actions associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended. A target-based action is one that is associated with a target.

Key Technologies

Displays top ten key technologies for the company and its subsidiaries based on frequency (technologies occurring with high and identical frequency are always included, and this may result in more than ten Key Technologies being listed). Includes both key technologies associated with patents where the company relationship is patent owner and key technologies associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

[Return to Table of Contents](#)



TABLE OF CONTENTS

Company Overview..... 5

Company Profile..... 6

Product Portfolio Summary..... 7

Product Portfolio Drug Pipeline Detail..... 13

 Phase 3 Clinical..... 14

 Phase 2 Clinical..... 20

 Phase 1 Clinical..... 26

 Discovery..... 36

[Return to Table of Contents](#)

MacroGenics Inc

COMPANY OVERVIEW

Company Name	MacroGenics Inc
Parent Company Name	MacroGenics Inc
Website	http://www.macrogenics.com/
Country	US
Number of Drugs in Active Development	13
Number of Inactive Drugs	14
Number of Patents as Owner	56
Number of Patents as Third Party	1
Number of Deals	34
Key Indications	Cancer,Autoimmune disease,Solid tumor,Insulin dependent diabetes,Breast tumor,Inflammatory disease,Rheumatoid arthritis,Systemic lupus erythematosus,Acute myelogenous leukemia,Chikungunya virus infection,Dengue virus infection,Esophagus tumor,Influenza virus infection,Transplant rejection,Variola virus infection
Key Target-based Actions	Immunoglobulin gamma Fc receptor III antagonist,CD276 antigen inhibitor,ErbB2 tyrosine kinase receptor inhibitor,Immunoglobulin gamma Fc receptor II antagonist,Immunoglobulin gamma Fc receptor II modulator,B-lymphocyte antigen CD20 inhibitor,Insulin-like growth factor 1 antagonist,ADAM-9 modulator,B-lymphocyte antigen CD19 modulator,CD79b agonist,CD79b modulator,CDw123 modulator,Carboxypeptidase inhibitor,Cell surface A33 antigen modulator,Epidermal growth factor antagonist,Immunoglobulin gamma Fc receptor II agonist,Oncostatin M
Key Technologies	Biological therapeutic,Parenteral formulation unspecified,Monoclonal antibody humanized,Antibody,Multivalent antibody,Monoclonal antibody,Intravenous formulation,Injectable formulation,Humanized antibody,Chimeric antibody,Drug combination,Immunoglobulin-G

COMPANY PROFILE

SUMMARY

MacroGenics Inc, incorporated in August 2000 and based in Rockville, Maryland, is focused on the development of novel immunotherapeutics. Product candidates include monoclonal antibodies and vaccines for the treatment and prevention of cancer, autoimmune and infectious disease. Programs are derived from both in-house discoveries and in-licensed candidates.

COMPANY LOCATION

MacroGenics is headquartered in Rockville, Maryland. The company has developed platform technology at three sites. These include protein engineering and animal modeling in Rockville, proteomics and target discovery in Seattle, Washington and genetic immunization and vaccine development in Dallas, Texas. In October 2005, MacroGenics opened a cGMP manufacturing facility in Rockville, MD. In February 2014, MacroGenics planned to expand its manufacturing facility, to increase its production capacity, using approximately US \$5 to 10 million.

ACQUISITIONS AND SPIN-OFFS

In July 2008, MacroGenics acquired Raven Biotechnologies. The company would issue shares of its common stock in the transaction but further financial details were not disclosed.

In June 2002, MacroGenics acquired Eliance Biotechnology Inc, a private vaccine discovery company located in Dallas,TX, which was founded to exploit technology developed at The University of Texas Southwestern Medical Center at Dallas Center for Biomedical Inventions. The company and university also formed an alliance to discover and develop immunotherapeutics to prevent and treat cancer, autoimmune and infectious diseases. In the same month, MacroGenics raised \$12.6 million in financing.

[Return to Table of Contents](#)



LICENSING AGREEMENTS

In October 2004, MacroGenics acquired exclusive rights to develop compounds against a cancer target identified using OriGene Technologies Inc's Rapid-Scan technology. MacroGenics was to focus on the development of therapeutic monoclonal antibody candidates against this molecule. OriGene would receive option fees, milestones and royalty payments.

In April 2004, Neose Technologies Inc and MacroGenics entered into a monoclonal antibodies research collaboration and license agreement. Neose was to apply its GlycoAdvance and GlycoPEGylation technologies to improve the therapeutic properties of MacroGenics compounds. MacroGenics had the right to take remodeled compounds into development. Following the initial research phase, MacroGenics was to be responsible for funding the further development of these licensed compounds. In exchange, Neose was to be entitled to receive option fee, milestone, and royalty payments as products were developed and commercialized.

In May 2002, MacroGenics licensed a therapeutic target induced by Epstein-Barr virus from EBVax Inc and Tufts University. MacroGenics was to launch a research program to identify treatments to reduce morbidity in patients suffering from the acute and chronic consequences of EBV infection. For a worldwide, exclusive license to the technology, MacroGenics agreed to certain upfront fees, milestone and royalty payments contingent on achieving specific preclinical and clinical objectives in different clinical indications.

In September 2001, MacroGenics reported the completion of several key license agreements relating to its core intellectual property.

EARLY R&D

IN OCTOBER 2010, BOEHRINGER INGELHEIM AND MACROGENICS ENTERED A GLOBAL ALLIANCE TO DISCOVER, DEVELOP AND COMMERCIALIZE ANTIBODY THERAPEUTICS, BASED ON MACROGENICS' DUAL-AFFINITY RE-TARGETING (DART) PLATFORM, WHICH WOULD BE DIRECTED AGAINST UP TO TEN COMBINATIONS OF MOLECULAR TARGETS. THERAPEUTIC AREAS FOR THE DRUG CANDIDATES COULD INCLUDE IMMUNOLOGY, ONCOLOGY, RESPIRATORY, CARDIOMETABOLIC AND INFECTIOUS DISEASES. THE COMPANIES WOULD SHARE DISCOVERY AND CERTAIN PRECLINICAL ACTIVITY RESPONSIBILITY. AFTERWHICH, BOEHRINGER INGELHEIM WOULD BE SOLELY RESPONSIBLE FOR FURTHER PRECLINICAL, CLINICAL, REGULATORY, COMMERCIAL AND MANUFACTURING ACTIVITIES OF ANY RESULTING PRODUCTS. MACROGENICS WAS EXPECTED TO RECEIVE \$60 MILLION, COMPRISED OF AN UPFRONT CASH PAYMENT, ANNUAL MAINTENANCE FEES, R&D FUNDING, AND NEAR-TERM RESEARCH-BASED MILESTONES, DURING THE FIRST THREE YEARS OF THE ALLIANCE. BOEHRINGER INGELHEIM ALSO EXPECTED TO MAKE A FUTURE EQUITY INVESTMENT IN MACROGENICS. FURTHERMORE, MACROGENICS COULD RECEIVE DEVELOPMENT, REGULATORY AND COMMERCIAL MILESTONE PAYMENTS OF UP TO \$210 MILLION FOR EACH OF THE TEN DART PROGRAMS, PLUS TIERED ROYALTIES. MACROGENICS WOULD HAVE AN OPTION TO COPROMOTE CERTAIN DART PRODUCTS IN THE US.

FINANCIAL

In February 2014, MacroGenics commenced an underwritten public offering of 2.5 million shares of its common stock, consisting of 1.5 million shares to be offered by MacroGenics and 1 million shares to be offered by existing stockholders. The underwriters were to be granted a 30-day option to purchase up to 375,000 shares of common stock; later that month, the company priced the offering of 3 million shares of its common stock, consisting of 1.8 million shares to be offered by MacroGenics and 1.2 million shares to be offered by existing stockholders at a price of \$36.50 per share. The underwriters were granted a 30-day option to purchase up to 450,000 shares of common stock. The offering was expected to close on February 18, 2014. Later in February 2014, the offering was completed for net proceeds of \$76.7 million, including \$15.4 million of net proceeds from full exercise of underwriters' over-allotment option.

In October 2013, MacroGenics offered an initial public offering of 5 million shares of its common stock, priced at \$16 per share. Underwriters were granted a 30-day option to purchase up to an additional 750,000 shares of common stock to cover any over-allotments. The shares were to be traded on the NASDAQ Global Select Market under the ticker symbol "MGNX". The offering was expected to close on October 16, 2013. Later that month, shares of MacroGenics began trading on the NASDAQ Global Select Market. Later that month, the offering was closed and the company raised \$83.8 million from the offering. The company offered 5,750,000 million shares of its common stock, at a price of \$16 per share. Underwriters were granted a 30-day option to purchase up to an additional 750,000 shares of common stock to cover any over-allotments.

In September 2008, MacroGenics raised \$25 million from a series D-2 financing round.

In May 2006, MacroGenics raised \$45 million from a series C financing round. The proceeds were to be used to fund development of the company's anti-CD3 antibody; in phase II trials for type 1 diabetes and to advance drug programs in autoimmune diseases and cancer.

[Return to Table of Contents](#)




PRODUCT PORTFOLIO SUMMARY

DRUGS

Drugs by Indication

Active Drugs by Indication Chart



[Return to Table of Contents](#)


Drugs by Indication Table

Indication	Active	Inactive	Total
Neoplasm	6	10	16
Immune disorder	3	4	7
Infectious disease	4	2	6
Gastrointestinal disease	2	3	5
Respiratory disease	1	3	4
Inflammatory disease	2	1	3
Genitourinary disease	0	3	3
Endocrine disease	2	1	3
Hematological disease	1	2	3
Neurological disease	0	2	2
Dermatological disease	1	1	2
Metabolic disorder	2	0	2
Musculoskeletal disease	1	1	2
Gynecology and obstetrics	1	1	2
Andrology	0	1	1

[Return to Table of Contents](#)

Drugs by Highest Status

Active Drugs by Highest Status Chart



Drugs by Highest Status Table

Development Status	Number of Drugs
Phase 3 Clinical	1
Phase 2 Clinical	1
Phase 1 Clinical	2
Discovery	9
Discontinued	3
No Development Reported	11

[Return to Table of Contents](#)

DEALS

Deal Type	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Technology - Other Proprietary	3	0	1	0	4
Drug - Funding	6	0	0	0	6
Drug - Screening/Evaluation	2	0	0	0	2
Drug - Early Research/Development	0	0	3	0	3
Drug - Development/Commercialization License	10	0	4	0	15
Drug - Manufacturing/Supply	0	0	2	0	2
Drug - Development Services	0	0	1	0	1
Technology - Delivery/Formulation	0	0	1	0	1

CLINICAL TRIALS

Trials by Condition Studied

Condition Studied	Ongoing	All
Endocrine disease	1	10
Gastrointestinal disease	0	9
Metabolic disorder	0	7
Neoplasm	2	7
Immune disorder	0	3
Infectious disease	0	3
Neurological disease	0	3
Inflammatory disease	0	3
Gynecology and obstetrics	1	2
Dermatological disease	0	2
Musculoskeletal disease	0	2
Hematological disease	1	1
Genitourinary disease	0	1
Respiratory disease	0	1

[Return to Table of Contents](#)

Trials by Phase

Phase	Ongoing	All
Phase 3	0	2
Phase 2	1	6
Phase 1	1	11
Phase not specified	0	1

Phase Definitions

Phase 3 Clinical

Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

Phase 2 Clinical

Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)

Phase 1 Clinical

Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

PATENTS *

Indication	As Owner	As Third Party	Total
Cardiovascular disease	2	0	2
Endocrine disease	19	1	20
Gastrointestinal disease	19	1	20
Genitourinary disease	12	1	13
Hematological disease	9	0	9
Andrology	8	0	8
Immune disorder	31	0	31
Musculoskeletal disease	13	0	13
Neoplasm	43	1	44
Ocular disease	3	0	3
Metabolic disorder	10	0	10
Mouth disease	1	0	1
Neurological disease	10	0	10
Respiratory disease	10	1	11
Infectious disease	18	0	18

[Return to Table of Contents](#)



Injury	1	0	1
Toxicity and intoxication	1	0	1
Inflammatory disease	23	0	23
Otorhinolaryngological disease	1	0	1
Gynecology and obstetrics	13	1	14
Dermatological disease	13	1	14
Surgical procedure	1	0	1

* This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

[Return to Table of Contents](#)

PRODUCT PORTFOLIO DRUG PIPELINE DETAIL

PLEASE NOTE: Highest status refers to highest development of that drug for one of the active companies

teplizumab

teplizumab SNAPSHOT

Drug Name	teplizumab
Key Synonyms	teplizumab
Originator Company	Tolera Therapeutics Inc
Active Companies	MacroGenics Inc
Inactive Companies	Tolera Therapeutics Inc;Eli Lilly & Co
Highest Status	Phase 3 Clinical
Active Indications	Transplant rejection;Insulin dependent diabetes
Target-based Actions	
Other Actions	CD3 antagonist;Immunosuppressant;Anti-inflammatory;Hypoglycemic agent
Technologies	Monoclonal antibody;Subcutaneous formulation;Intravenous formulation;Infusion;Biological therapeutic
Last Change Date	04-Dec-2013

teplizumab DEVELOPMENT PROFILE

SUMMARY

MacroGenics (following an acquisition from Tolera Therapeutics) is developing teplizumab (hOKT3gamma1(Ala-Ala); MGA-031), an injectable non-FcR binding anti-CD3 monoclonal antibody, for the potential prevention and treatment of type 1 diabetes in relatives 'at risk' and 'early onset',. MacroGenics, in partnership with Lilly, had been developing teplizumab for the treatment of type 1 diabetes. A phase III trial in patients with recent-onset type 1 diabetes began in June 2009. However, in October 2010, an analysis by a Data Monitoring Committee found that the PROTEGE trial would not meet its primary endpoint and dosing in all trials was suspended. By January 2011, Lilly had terminated its development of the drug and by June 2011, MacroGenics only listed type 1 diabetes in relatives 'at risk' on its pipeline ; in October 2011, the drug was listed as being in phase III, presumed to be for both 'early onset' and 'at risk' ; however, in December 2013, the drug was in phase II development.

MacroGenics was also developing teplizumab for the treatment of islet transplantation; however, development is assumed to have been suspended following the suspension of trials in type 1 diabetes . The drug was also being developed for the treatment of psoriatic arthritis ; however, no development has been reported for this indication.

teplizumab DEVELOPMENT STATUS

CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
---------	------------	---------	--------------------	------

[Return to Table of Contents](#)



Company	Indication	Country	Development Status	Date
MacroGenics Inc	Insulin dependent diabetes	Europe	Phase 3 Clinical	02-Aug-2007
MacroGenics Inc	Insulin dependent diabetes	North America	Phase 3 Clinical	02-Aug-2007
MacroGenics Inc	Transplant rejection	US	Suspended	20-Oct-2010
Eli Lilly & Co	Insulin dependent diabetes	Europe	Discontinued	27-Jan-2011
Eli Lilly & Co	Insulin dependent diabetes	North America	Discontinued	27-Jan-2011
Tolera Therapeutics Inc	Insulin dependent diabetes	US	Discontinued	18-Jul-2005
Eli Lilly & Co	Psoriatic arthritis	US	No Development Reported	18-Apr-2009
MacroGenics Inc	Psoriatic arthritis	US	No Development Reported	28-Apr-2007

teplizumab DRUG NAMES

Names	Type
teplizumab	USAN, INN
anti-CD3 antibody (diabetes, psoriatic arthritis), MacroGenics	
anti-CD3 antibody (diabetes, psoriatic arthritis), Tolerance Therapeutics	
hOKT3gamma-1 (Ala-Ala), MacroGenics	
hOKT3gl (Ala-Ala), Tolerance Therapeutics	
MGA-031	Research Code
hOKT3gl (Ala-Ala), MacroGenics	
hOKT3gamma-1 (Ala-Ala), Tolerance Therapeutics	

teplizumab CLINICAL TRIALS

Trials by Phase and Condition Studied

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Insulin dependent diabetes											
0	0	0	2	1	5	0	7	0	1	1	15
Hypoglycemia											
0	0	0	0	0	0	0	2	0	0	0	2

[Return to Table of Contents](#)

Psoriatic arthritis											
0	0	0	0	0	0	0	1	0	0	0	1
Hematological neoplasm											
0	0	0	0	0	1	0	0	0	0	0	1
Osteopetrosis											
0	0	0	0	0	0	0	0	0	1	0	1
Kidney transplant rejection											
0	0	0	1	0	0	0	0	0	0	0	1
Psoriasis											
0	0	0	0	0	1	0	0	0	0	0	1
Renal tumor											
0	0	0	0	0	1	0	0	0	0	0	1
Rheumatoid arthritis											
0	0	0	0	0	1	0	0	0	0	0	1
Arthritis											
0	0	0	0	0	1	0	0	0	0	0	1
Colorectal tumor											
0	0	0	0	0	1	0	0	0	0	0	1
Ovary tumor											
0	0	0	0	0	1	0	0	0	0	0	1

Total Trials by Phase and Status

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Total by Phase and Status											
0	0	0	3	1	12	0	9	0	2	1	26

Phase Definitions

Phase 3 Clinical

Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

Phase 2 Clinical

[Return to Table of Contents](#)

Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)


Phase 1 Clinical

Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

teplizumab DEALS AND PATENTS

DEALS

Deals by Parent Company Chart




Deals by Parent Company Table

Company Name	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
MacroGenics Inc	2	1	1	0	4
Juvenile Diabetes Research Foundation	0	0	2	0	2
Eli Lilly & Co	0	0	1	1	2
Tolera Therapeutics Inc	1	0	0	0	1
PDL BioPharma Inc	1	0	0	0	1
Yale University	1	0	0	0	1
ImaginAb Inc	0	0	1	0	1

[Return to Table of Contents](#)

Deals by Type Chart




Deals by Type Table

Deal Type	Active	Inactive	Total
Drug - Funding	2	0	2
Drug - Development/Commercialization License	1	1	2
Technology - Other Proprietary	1	0	1
Patent - Non-Exclusive Rights	1	0	1

[Return to Table of Contents](#)

PATENTS

Patents by Parent Company Chart




Patents by Parent Company Table

Company Name	As Owner	As Third Party	Total
MacroGenics Inc	7	0	7
Columbia University	1	1	2
Tolera Therapeutics Inc	2	0	2
Osaka University	1	0	1
University of Chicago	1	0	1
Juvenile Diabetes Research Foundation	1	0	1
University of California	1	0	1
Eli Lilly & Co	1	0	1
La Jolla Institute of Allergy & Immunology	1	0	1
Johnson & Johnson	1	0	1
Massachusetts General Hospital	1	0	1

[Return to Table of Contents](#)

Patents by Drug Relationship Type Chart



Patents by Drug Relationship Type Table

Drug Relationship	Total
New use	5
Component of Combination	2
Product	1
General interest	1
Formulation	1

margetuximab

margetuximab SNAPSHOT

Drug Name	margetuximab
Key Synonyms	margetuximab
Originator Company	MacroGenics Inc
Active Companies	MacroGenics Inc;Green Cross Corp
Inactive Companies	
Highest Status	Phase 2 Clinical
Active Indications	Esophagus tumor;Solid tumor;Breast tumor
Target-based Actions	ErbB2 tyrosine kinase receptor inhibitor
Other Actions	Anticancer monoclonal antibody;Anticancer protein kinase inhibitor
Technologies	Monoclonal antibody;Intravenous formulation;Infusion;Biological therapeutic
Last Change Date	19-Jun-2014

margetuximab DEVELOPMENT PROFILE

SUMMARY

MacroGenics, in collaboration with Green Cross, is developing margetuximab (MGAH-22), the lead in a series of next-generation Fc optimized anti-HER2/neu mAb that is an "improved"/biobetter version of trastuzumab, for the potential iv treatment of solid tumors, including breast cancer. In April 2013, a phase II trial in relapsed or refractory advanced breast cancer was initiated. In November 2013, a phase III study for advanced gastroesophageal cancer was expected to begin in the second half of 2014. By August 2008, MacroGenics was seeking to outlicense the program to partners; in November 2012, this was still the case.

margetuximab DEVELOPMENT STATUS

CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
MacroGenics Inc	Breast tumor	US	Phase 2 Clinical	01-Jan-2001
Green Cross Corp	Solid tumor	South Korea	Phase 1 Clinical	06-Jan-2011
MacroGenics Inc	Solid tumor	South Korea	Phase 1 Clinical	06-Jan-2011
MacroGenics Inc	Esophagus tumor	US	Discovery	12-Nov-2013

[Return to Table of Contents](#)



margetuximab DRUG NAMES

Names	Type
trastuzumab biobetter (cancer), Korea Green Cross/ MacroGenics	
next-generation anti-Her2/neu mAbs (cancer), MacroGenics	
MGAH-22	Research Code
margetuximab	USAN, INN

margetuximab CLINICAL TRIALS

Trials by Phase and Condition Studied

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On- going	All	On- going	All	On- going	All	On- going	All	On- going	All	On- going	All
Breast tumor											
0	0	0	0	0	0	0	2	0	0	0	2
Metastatic breast cancer											
0	0	0	0	1	1	0	0	0	0	1	1
Cancer											
0	0	0	0	0	0	0	1	0	0	0	1
Stomach tumor											
0	0	0	0	0	0	0	1	0	0	0	1
Non-small-cell lung cancer											
0	0	0	0	0	0	0	1	0	0	0	1
Ovary tumor											
0	0	0	0	0	0	0	1	0	0	0	1
Bladder cancer											
0	0	0	0	0	0	0	1	0	0	0	1

[Return to Table of Contents](#)

Total Trials by Phase and Status

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Total by Phase and Status											
0	0	0	0	1	1	0	2	0	0	1	3

Phase Definitions

Phase 3 Clinical

Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

Phase 2 Clinical

Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)


Phase 1 Clinical

Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

margetuximab DEALS AND PATENTS

DEALS

Deals by Parent Company Chart




[Return to Table of Contents](#)

Deals by Parent Company Table

Company Name	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Green Cross Corp	0	0	1	0	1
MacroGenics Inc	1	0	0	0	1

Deals by Type Chart




Deals by Type Table

Deal Type	Active	Inactive	Total
Drug - Development/Commercialization License	1	0	1

[Return to Table of Contents](#)

PATENTS


Patents by Parent Company Chart



Patents by Parent Company Table

Company Name	As Owner	As Third Party	Total
MacroGenics Inc	5	0	5

Patents by Drug Relationship Type Chart



[Return to Table of Contents](#)

Patents by Drug Relationship Type Table

Drug Relationship	Total
General interest	3
Tentative	2

[Return to Table of Contents](#)

MGD-006

MGD-006 SNAPSHOT

Drug Name	MGD-006
Key Synonyms	
Originator Company	MacroGenics Inc
Active Companies	Servier;MacroGenics Inc
Inactive Companies	
Highest Status	Phase 1 Clinical
Active Indications	Acute myelogenous leukemia
Target-based Actions	CDw123 modulator
Other Actions	CD3 modulator;Anticancer protein kinase inhibitor
Technologies	Multivalent antibody;Humanized antibody;Injectable formulation;Biological therapeutic;Parenteral formulation unspecified
Last Change Date	22-Jul-2014

MGD-006 DEVELOPMENT PROFILE

SUMMARY

MacroGenics, in collaboration with Servier, developing MGD-006 (S-80880), a bispecific humanized antibody which acts on CD123 and CD3, based on MacroGenics' Dual-Affinity Re-Targeting (DART) technology, for the potential injectable treatment of acute myeloid leukemia,. In May 2014, a phase I study was initiated in the US. At that time, the study was expected to be completed in January 2017. In November 2013, the company was seeking to outlicense the drug.

MGD-006 DEVELOPMENT STATUS

CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
MacroGenics Inc	Acute myelogenous leukemia	US	Phase 1 Clinical	28-May-2014
Servier	Acute myelogenous leukemia	France	Discovery	06-Nov-2013

MGD-006 DRUG NAMES

Names	Type
S-80880	Research Code
MGD-006	Research Code

[Return to Table of Contents](#)

MGD-006 CLINICAL TRIALS

Trials by Phase and Condition Studied

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Acute myelogenous leukemia											
0	0	0	0	0	0	1	1	0	0	1	1

Total Trials by Phase and Status

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Total by Phase and Status											
0	0	0	0	0	0	1	1	0	0	1	1

Phase Definitions

Phase 3 Clinical

Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

Phase 2 Clinical

Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)


Phase 1 Clinical

Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

[Return to Table of Contents](#)

DEALS

Deals by Parent Company Chart




Deals by Parent Company Table

Company Name	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
MacroGenics Inc	1	0	0	0	1
Servier	0	0	1	0	1

[Return to Table of Contents](#)

Deals by Type Chart



Deals by Type Table

Deal Type	Active	Inactive	Total
Drug - Development/Commercialization License	1	0	1

[Return to Table of Contents](#)

MGA-271

MGA-271 SNAPSHOT

Drug Name	MGA-271
Key Synonyms	
Originator Company	MacroGenics Inc
Active Companies	Servier;MacroGenics Inc
Inactive Companies	
Highest Status	Phase 1 Clinical
Active Indications	Solid tumor
Target-based Actions	CD276 antigen inhibitor
Other Actions	Anticancer monoclonal antibody;Immunostimulant
Technologies	Monoclonal antibody humanized;Immunoglobulin-G;Intravenous formulation;Biological therapeutic;Protein recombinant
Last Change Date	08-May-2014

MGA-271 DEVELOPMENT PROFILE

SUMMARY

MacroGenics and licensee Servier are developing MGA-271 (Anti-B7-H3), a humanized IgG1/kappa, Fc-optimized mAb that binds B7-H3 (CD276) found on differentiated cancer cells and cancer stem cells, for the potential iv treatment of various solid tumors, including prostate, renal and pancreatic cancers as well as melanomas,. In July 2011, a phase I trial was initiated . By April 2012, recruitment for a phase I/IIa trial in B7-H3-positive metastatic/recurrent adenocarcinoma was underway. In August 2013, the phase I dose-expansion trial had begun. In May 2014, monotherapy and combination studies were expected to be initiated in the second half of 2014 and in 2015, respectively. In November 2013, MacroGenics was seeking to outlicense MGA-271.

MGA-271 DEVELOPMENT STATUS

CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
MacroGenics Inc	Solid tumor	US	Phase 1 Clinical	07-Jul-2011
Servier	Solid tumor	France	Phase 1 Clinical	01-Dec-2011

[Return to Table of Contents](#)

MGA-271 DRUG NAMES

Names	Type
MGA-271	Research Code
Anti-B7-H3	

MGA-271 CLINICAL TRIALS

Trials by Phase and Condition Studied

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Melanoma											
0	0	0	0	0	0	0	1	0	0	0	1
Cancer											
0	0	0	0	0	0	0	1	0	0	0	1

Total Trials by Phase and Status

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Total by Phase and Status											
0	0	0	0	0	0	0	2	0	0	0	2

Phase Definitions

Phase 3 Clinical

Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

Phase 2 Clinical

Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)

Phase 1 Clinical

Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0


[Return to Table of Contents](#)



MGA-271 DEALS AND PATENTS

DEALS

Deals by Parent Company Chart




Deals by Parent Company Table

Company Name	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
MacroGenics Inc	2	0	0	0	2
Servier	0	0	1	0	1
ImaginAb Inc	0	0	1	0	1

[Return to Table of Contents](#)

Deals by Type Chart




Deals by Type Table

Deal Type	Active	Inactive	Total
Technology - Other Proprietary	1	0	1
Drug - Development/Commercialization License	1	0	1

[Return to Table of Contents](#)

PATENTS


Patents by Parent Company Chart



Patents by Parent Company Table

Company Name	As Owner	As Third Party	Total
MacroGenics Inc	1	0	1

Patents by Drug Relationship Type Chart



[Return to Table of Contents](#)

Patents by Drug Relationship Type Table

Drug Relationship	Total
General interest	1

[Return to Table of Contents](#)

monoclonal antibody cocktail (DART, smallpox), MacroGenics

monoclonal antibody cocktail (DART, smallpox), MacroGenics SNAPSHOT

Drug Name	monoclonal antibody cocktail (DART, smallpox), MacroGenics
Key Synonyms	
Originator Company	MacroGenics Inc
Active Companies	MacroGenics Inc
Inactive Companies	
Highest Status	Discovery
Active Indications	Variola virus infection
Target-based Actions	
Other Actions	Unspecified drug target;Antiviral
Technologies	Monoclonal antibody humanized;Drug combination;Biological therapeutic;Parenteral formulation unspecified
Last Change Date	14-Feb-2013

monoclonal antibody cocktail (DART, smallpox), MacroGenics DEVELOPMENT PROFILE

SUMMARY

MacroGenics is investigating a mAb cocktail, based on its Dual-Affinity Re-Targeting (DART) technology, targeting B5R and A33R (extracellular enveloped virions-specific proteins), and A27L and L1R (intracellular mature virions-specific proteins), as a potential post-exposure prophylaxis for smallpox. By August 2008, preclinical studies were underway ; in February 2013, the program was listed as being in lead optimization. In August 2008, MacroGenics was seeking to outlicense the partnering rights to the product ; in May 2011, this was still the case.

monoclonal antibody cocktail (DART, smallpox), MacroGenics DEVELOPMENT STATUS

CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
MacroGenics Inc	Variola virus infection	US	Discovery	15-Jul-2006

[Return to Table of Contents](#)


monoclonal antibody cocktail (DART, smallpox), MacroGenics DRUG NAMES

Names	Type
mAb cocktail (variola virus infection), MacroGenics	
extracellular enveloped/intracellular mature virions-specific protein inhibitor (smallpox), MacroGenics	
monoclonal antibody cocktail (DART, smallpox), MacroGenics	
B5R/A33R/A27L/L1R inhibitor (smallpox), MacroGenics	

monoclonal antibody cocktail (DART, smallpox), MacroGenics DEALS AND PATENTS

DEALS

Deals by Parent Company Chart




Deals by Parent Company Table

Company Name	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
US Government	0	0	1	0	1
MacroGenics Inc	1	0	0	0	1

[Return to Table of Contents](#)

Deals by Type Chart




Deals by Type Table

Deal Type	Active	Inactive	Total
Drug - Funding	1	0	1

[Return to Table of Contents](#)

PATENTS


Patents by Parent Company Chart



Patents by Parent Company Table

Company Name	As Owner	As Third Party	Total
MacroGenics Inc	1	0	1

Patents by Drug Relationship Type Chart



[Return to Table of Contents](#)

Patents by Drug Relationship Type Table

Drug Relationship	Total
Tentative	1

H5N1 influenza mAb therapy, MacroGenics

H5N1 influenza mAb therapy, MacroGenics SNAPSHOT

Drug Name	H5N1 influenza mAb therapy, MacroGenics
Key Synonyms	
Originator Company	MacroGenics Inc
Active Companies	MacroGenics Inc
Inactive Companies	
Highest Status	Discovery
Active Indications	Influenza virus infection
Target-based Actions	
Other Actions	Antiviral;Unspecified drug target
Technologies	Monoclonal antibody humanized;Biological therapeutic;Parenteral formulation unspecified
Last Change Date	15-Feb-2013

H5N1 influenza mAb therapy, MacroGenics DEVELOPMENT PROFILE

SUMMARY

MacroGenics is investigating cross-neutralizing humanized mAbs, for the potential post-exposure prophylaxis of H5N1 avian influenza virus infection. By August 2009, lead optimization studies were ongoing ; in February 2013, development was ongoing. In May 2011, the company's strategy involved seeking to outlicense its programs.

H5N1 influenza mAb therapy, MacroGenics DEVELOPMENT STATUS

CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
MacroGenics Inc	Influenza virus infection	US	Discovery	03-Oct-2006


H5N1 influenza mAb therapy, MacroGenics DRUG NAMES

Names	Type
H5N1 influenza mAb therapy, MacroGenics	
H5N1 avian influenza monoclonal antibody therapy, MacroGenics	

[Return to Table of Contents](#)

DEALS

Deals by Parent Company Chart




Deals by Parent Company Table

Company Name	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
US Government	0	0	1	0	1
MacroGenics Inc	1	0	0	0	1

[Return to Table of Contents](#)

Deals by Type Chart



Deals by Type Table

Deal Type	Active	Inactive	Total
Drug - Funding	1	0	1

[Return to Table of Contents](#)

CD32BxCD79B DART antibody (autoimmune disease), MacroGenics

CD32BxCD79B DART antibody (autoimmune disease), MacroGenics SNAPSHOT

Drug Name	CD32BxCD79B DART antibody (autoimmune disease), MacroGenics
Key Synonyms	
Originator Company	MacroGenics Inc
Active Companies	MacroGenics Inc
Inactive Companies	
Highest Status	Discovery
Active Indications	Inflammatory disease;Autoimmune disease
Target-based Actions	CD79b agonist;Immunoglobulin gamma Fc receptor II agonist
Other Actions	Anti-inflammatory;Anticancer
Technologies	Antibody;Biological therapeutic
Last Change Date	04-Dec-2013

CD32BxCD79B DART antibody (autoimmune disease), MacroGenics DEVELOPMENT PROFILE

SUMMARY

MacroGenics is investigating CD32BxCD79B dual affinity re-targeting (DART) antibody, comprised of dual specificity for B-cells by incorporating specificity for the B-cell receptor (Cluster of Differentiation 79B, CD79B) and an inhibitory receptor (Fc gamma receptor IIb, CD32B), that specifically target activated B-cells while sparing resting B-cells, the lead from the series of DARTs, for the potential treatment of inflammation and autoimmune diseases including lupus, rheumatoid arthritis, multiple sclerosis and other disorders . In May 2011, the program was listed as being in preclinical development ; in December 2013, this was still the case. In August 2008, MacroGenics was seeking to outlicense partnering rights; in December 2013, this was still the case.

The company was previously investigating the series for cancer and allergy however by November 2010, these indications were no longer listed on the company's development pipeline.

CD32BxCD79B DART antibody (autoimmune disease), MacroGenics DEVELOPMENT STATUS

CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
MacroGenics Inc	Autoimmune disease	US	Discovery	05-Aug-2008
MacroGenics Inc	Inflammatory disease	US	Discovery	13-Aug-2009
MacroGenics Inc	Allergy	US	No Development Reported	15-Nov-2010
MacroGenics Inc	Cancer	US	No Development Reported	15-Nov-2010

[Return to Table of Contents](#)


CD32BxCD79B DART antibody (autoimmune disease), MacroGenics DRUG NAMES

Names	Type
DART antibodies (autoimmune disease), MacroGenics	
dual affinity CD32-based proteins (cancer/allergy/autoimmune disease), MacroGenics	
CD32BxCD79B DART antibody (autoimmune disease), MacroGenics	

CD32BxCD79B DART antibody (autoimmune disease), MacroGenics DEALS AND PATENTS

DEALS

Deals by Parent Company Chart




Deals by Parent Company Table

Company Name	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
MacroGenics Inc	1	0	1	0	2
US Government	0	0	1	0	1
Abzena plc	1	0	0	0	1

[Return to Table of Contents](#)

Deals by Type Chart




Deals by Type Table

Deal Type	Active	Inactive	Total
Drug - Funding	1	0	1
Technology - Delivery/Formulation	1	0	1

[Return to Table of Contents](#)

PATENTS

Patents by Parent Company Chart




Patents by Parent Company Table

Company Name	As Owner	As Third Party	Total
Boehringer Ingelheim Corp	2	0	2
MacroGenics Inc	2	0	2
Pfizer Inc	2	0	2

[Return to Table of Contents](#)

Patents by Drug Relationship Type Chart



Patents by Drug Relationship Type Table

Drug Relationship	Total
General interest	1
Product	1

[Return to Table of Contents](#)

humanized mAbs (Chikungunya virus infection), MacroGenics/Washington University

humanized mAbs (Chikungunya virus infection), MacroGenics/Washington University SNAPSHOT

Drug Name	humanized mAbs (Chikungunya virus infection), MacroGenics/Washington University
Key Synonyms	
Originator Company	MacroGenics Inc
Active Companies	Washington University in St Louis;MacroGenics Inc
Inactive Companies	
Highest Status	Discovery
Active Indications	Chikungunya virus infection
Target-based Actions	
Other Actions	Unspecified drug target;Antiviral
Technologies	Monoclonal antibody humanized;Biological therapeutic;Parenteral formulation unspecified
Last Change Date	14-Feb-2013

humanized mAbs (Chikungunya virus infection), MacroGenics/Washington University DEVELOPMENT PROFILE

SUMMARY

MacroGenics and Washington University are investigating humanized mAbs for the potential prevention of Chikungunya virus infection,. By May 2010, development had been ongoing ; in February 2013, this was still the case. In May 2011, the company's strategy involved seeking to outlicense its programs.

humanized mAbs (Chikungunya virus infection), MacroGenics/Washington University DEVELOPMENT STATUS

CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
MacroGenics Inc	Chikungunya virus infection	US	Discovery	25-May-2010
Washington University in St Louis	Chikungunya virus infection	US	Discovery	25-May-2010

humanized mAbs (Chikungunya virus infection), MacroGenics/Washington University DRUG NAMES

Names	Type
humanized mAbs (Chikungunya virus infection), MacroGenics/Washington University	


[Return to Table of Contents](#)



humanized mAbs (Chikungunya virus infection), MacroGenics/Washington University DEALS AND PATENTS

DEALS

Deals by Parent Company Chart




Deals by Parent Company Table

Company Name	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Washington University in St Louis	2	0	0	0	2
US Government	0	0	1	0	1
MacroGenics Inc	0	0	1	0	1

[Return to Table of Contents](#)

Deals by Type Chart



Deals by Type Table

Deal Type	Active	Inactive	Total
Drug - Development/Commercialization License	1	0	1
Drug - Funding	1	0	1

[Return to Table of Contents](#)

bispecific antibodies (DART, cancer), MacroGenics/ Pfizer

bispecific antibodies (DART, cancer), MacroGenics/ Pfizer SNAPSHOT

Drug Name	bispecific antibodies (DART, cancer), MacroGenics/ Pfizer
Key Synonyms	
Originator Company	MacroGenics Inc
Active Companies	Pfizer Inc;MacroGenics Inc
Inactive Companies	
Highest Status	Discovery
Active Indications	Cancer
Target-based Actions	Epidermal growth factor antagonist;B-lymphocyte antigen CD19 modulator;Insulin-like growth factor 1 antagonist
Other Actions	CD3 agonist;Anticancer antibody;Anticancer protein kinase inhibitor
Technologies	Multivalent antibody;Biological therapeutic
Last Change Date	04-Dec-2013

bispecific antibodies (DART, cancer), MacroGenics/ Pfizer DEVELOPMENT PROFILE

SUMMARY

Pfizer and MacroGenics are investigating bispecific antibodies, based on MacroGenics' Dual-Affinity Re-Targeting (DART) technology, including bispecific antibodies that bind both the CD19 antigen and the T-cell receptor component CD3/TCR (CD19xCD3/TCR), and that bind EGFR and IGF1R (EGFRxIGF1R) for the potential treatment of cancer, including solid tumors like gastrointestinal tumors and liquid tumors like acute myeloid leukemia and other hematological cancers,. In June 2012, preclinical data were reported. In December 2013, the program was in preclinical development. In November 2012, the company was seeking to outlicense the program.

bispecific antibodies (DART, cancer), MacroGenics/ Pfizer DEVELOPMENT STATUS

CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
MacroGenics Inc	Cancer	US	Discovery	26-Oct-2010
Pfizer Inc	Cancer	US	Discovery	26-Oct-2010

[Return to Table of Contents](#)




bispecific antibodies (DART, cancer), MacroGenics/ Pfizer DRUG NAMES

Names	Type
IgDART (EGFRxIGF1R)	
bispecific antibodies (DART, cancer), MacroGenics/ Pfizer	
CD19xCD3 DART	
CD19xTCR DART	

bispecific antibodies (DART, cancer), MacroGenics/ Pfizer DEALS AND PATENTS

DEALS

Deals by Parent Company Chart



Deals by Parent Company Table

Company Name	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
MacroGenics Inc	2	0	0	0	2
ImaginAb Inc	0	0	1	0	1
Pfizer Inc	0	0	1	0	1

[Return to Table of Contents](#)

Deals by Type Chart



Deals by Type Table

Deal Type	Active	Inactive	Total
Drug - Development/Commercialization License	1	0	1
Technology - Other Proprietary	1	0	1

[Return to Table of Contents](#)

monoclonal antibody (DART, dengue virus infection), MacroGenics

monoclonal antibody (DART, dengue virus infection), MacroGenics SNAPSHOT

Drug Name	monoclonal antibody (DART, dengue virus infection), MacroGenics
Key Synonyms	
Originator Company	MacroGenics Inc
Active Companies	MacroGenics Inc
Inactive Companies	
Highest Status	Discovery
Active Indications	Dengue virus infection
Target-based Actions	
Other Actions	Unspecified drug target;Antiviral
Technologies	Immunoglobulin;Monoclonal antibody;Biological therapeutic;Parenteral formulation unspecified
Last Change Date	15-Feb-2013

monoclonal antibody (DART, dengue virus infection), MacroGenics DEVELOPMENT PROFILE

SUMMARY

MacroGenics is investigating an Ig-dual affinity re-targeting (Ig-DART) monoclonal antibody, which eliminates FcR binding, based on its DART platform, for the potential treatment and post-exposure prophylaxis of dengue virus infection. By September 2008, preclinical studies were underway ; in February 2013, the program was listed as being in lead optimization. In May 2011, the company was seeking to outlicense its products.

monoclonal antibody (DART, dengue virus infection), MacroGenics DEVELOPMENT STATUS

CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
MacroGenics Inc	Dengue virus infection	US	Discovery	05-Sep-2008


monoclonal antibody (DART, dengue virus infection), MacroGenics DRUG NAMES

Names	Type
monoclonal antibody (DART, dengue virus infection), MacroGenics	
Ig-DART mAb (dengue virus infection), MacroGenics	

[Return to Table of Contents](#)

DEALS

Deals by Parent Company Chart




Deals by Parent Company Table

Company Name	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
MacroGenics Inc	2	0	0	0	2
US Government	0	0	2	0	2

[Return to Table of Contents](#)

Deals by Type Chart



Deals by Type Table

Deal Type	Active	Inactive	Total
Drug - Funding	2	0	2

MGD-007

MGD-007 SNAPSHOT

Drug Name	MGD-007
Key Synonyms	
Originator Company	MacroGenics Inc
Active Companies	MacroGenics Inc;Servier
Inactive Companies	
Highest Status	Discovery
Active Indications	Cancer
Target-based Actions	Cell surface A33 antigen modulator
Other Actions	Anticancer antibody;CD3 modulator
Technologies	Multivalent antibody;Injectable formulation;Biological therapeutic;Parenteral formulation unspecified
Last Change Date	25-Jul-2014

MGD-007 DEVELOPMENT PROFILE

SUMMARY

MacroGenics, in collaboration with Servier, investigating MGD-007, a bispecific antibody which acts on gpA33 and CD3, based on MacroGenics' Dual-Affinity Re-Targeting (DART) technology, for the potential injectable treatment of cancer, including colorectal cancer . In November 2013, preclinical development was ongoing . An IND was approved by the US FDA for phase I trials of MGD-007 for colorectal cancer in July 2014. At that time, a trial was expected to begin in the second half of 2014 .

MGD-007 DEVELOPMENT STATUS

CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
MacroGenics Inc	Cancer	US	Discovery	06-Nov-2013
Servier	Cancer	France	Discovery	06-Nov-2013

MGD-007 DRUG NAMES


Names	Type
MGD-007	Research Code

[Return to Table of Contents](#)

MGD-007 DEALS AND PATENTS

DEALS

Deals by Parent Company Chart




Deals by Parent Company Table

Company Name	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
MacroGenics Inc	1	0	0	0	1
Servier	0	0	1	0	1

[Return to Table of Contents](#)

Deals by Type Chart



Deals by Type Table

Deal Type	Active	Inactive	Total
Drug - Development/Commercialization License	1	0	1

[Return to Table of Contents](#)

anti-CD3/undisclosed antibodies (DART/injectable, cancer), MacroGenics/Servier

anti-CD3/undisclosed antibodies (DART/injectable, cancer), MacroGenics/Servier SNAPSHOT

Drug Name	anti-CD3/undisclosed antibodies (DART/injectable, cancer), MacroGenics/Servier
Key Synonyms	
Originator Company	MacroGenics Inc
Active Companies	MacroGenics Inc;Servier
Inactive Companies	
Highest Status	Discovery
Active Indications	Cancer
Target-based Actions	
Other Actions	CD3 antagonist;Anticancer antibody
Technologies	Multivalent antibody;Injectable formulation;Biological therapeutic;Parenteral formulation unspecified
Last Change Date	04-Dec-2013

anti-CD3/undisclosed antibodies (DART/injectable, cancer), MacroGenics/Servier DEVELOPMENT PROFILE

SUMMARY

MacroGenics, in collaboration with Servier, is investigating bispecific antibodies targeting CD3 and an undisclosed target, based on MacroGenics' Dual-Affinity Re-Targeting (DART) technology, for the potential treatment of cancer. In November 2013, the program was in preclinical development and IND-enabling studies were expected to be initiated later that year. At that time, the company was seeking to outlicense the program.

anti-CD3/undisclosed antibodies (DART/injectable, cancer), MacroGenics/Servier DEVELOPMENT STATUS

CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
MacroGenics Inc	Cancer	US	Discovery	06-Nov-2013
Servier	Cancer	France	Discovery	06-Nov-2013

anti-CD3/undisclosed antibodies (DART/injectable, cancer), MacroGenics/Servier DRUG NAMES


Names	Type
anti-CD3/undisclosed antibodies (DART/injectable, cancer), MacroGenics/Servier	

[Return to Table of Contents](#)

anti-CD3/undisclosed antibodies (DART/injectable, cancer), MacroGenics/Servier DEALS AND PATENTS

DEALS

Deals by Parent Company Chart



Deals by Parent Company Table

Company Name	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Servier	0	0	1	0	1
MacroGenics Inc	1	0	0	0	1

[Return to Table of Contents](#)

Deals by Type Chart



Deals by Type Table

Deal Type	Active	Inactive	Total
Drug - Development/Commercialization License	1	0	1

[Return to Table of Contents](#)

MGD-010

MGD-010 SNAPSHOT

Drug Name	MGD-010
Key Synonyms	
Originator Company	MacroGenics Inc
Active Companies	MacroGenics Inc
Inactive Companies	
Highest Status	Discovery
Active Indications	Autoimmune disease;Systemic lupus erythematosus;Rheumatoid arthritis
Target-based Actions	Immunoglobulin gamma Fc receptor II modulator;CD79b modulator
Other Actions	Immunomodulator;Anti-inflammatory
Technologies	Multivalent antibody;Injectable formulation;Biological therapeutic;Parenteral formulation unspecified
Last Change Date	19-Jun-2014

MGD-010 DEVELOPMENT PROFILE

SUMMARY

MacroGenics is investigating MGD-010, a bispecific antibody that acts on CD32B and CD79B, based on MacroGenics' Dual-Affinity Re-Targeting (DART) technology, for the potential injectable treatment of autoimmune diseases, including rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). By November 2013, IND-enabling studies had been initiated. By December 2013, the company listed the drug in preclinical development for RA and SLE. By November 2013, the company was seeking to outlicense the drug.

MGD-010 DEVELOPMENT STATUS

CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
MacroGenics Inc	Autoimmune disease	US	Discovery	06-Nov-2013
MacroGenics Inc	Rheumatoid arthritis	US	Discovery	03-Dec-2013
MacroGenics Inc	Systemic lupus erythematosus	US	Discovery	03-Dec-2013

MGD-010 DRUG NAMES

Names	Type
MGD-010	Research Code


[Return to Table of Contents](#)



MGD-010 DEALS AND PATENTS

DEALS

Deals by Parent Company Chart



Active Deals
Total: 1


- MacroGenics Inc
- Takeda Pharmaceutical Co Ltd

Deals by Parent Company Table

Company Name	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Takeda Pharmaceutical Co Ltd	0	0	1	0	1
MacroGenics Inc	1	0	0	0	1

[Return to Table of Contents](#)

Deals by Type Chart



Deals by Type Table

Deal Type	Active	Inactive	Total
Drug - Development/Commercialization License	1	0	1

[Return to Table of Contents](#)

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information.

For more information about *Cortellis for Competitive Intelligence*, visit:

http://cortellis.thomsonreuters.com/cortellis_for_you/?cid=thomsonone.

For subscription information, e-mail scientific.lifesciences@thomsonreuters.com.

© 2012 Thomson Reuters. All rights reserved.
Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks and trademarks of Thomson Reuters and its affiliated companies.

[Return to Table of Contents](#)

